ALK and non-small cell lung carcinoma: Treatment with crizotinib in pediatric cancers such as NSCLC and IMT has shown an encouraging and efficient effect for tumors which harbor ALK fusion oncogenes (52), however, responses were less encouraging for treatment of pediatric neuroblastoma patients with crizotinib (53).